Advertisement

Topics

Biocon Ltd Company Profile

17:01 EDT 24th September 2018 | BioPortfolio


News Articles [43 Associated News Articles listed on BioPortfolio]

FDA Approves Mylan and Biocon’s Fulphila, the First Biosimilar to Neulasta

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, June 4, 2018/PRNewswire/ — Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U....

Biocon down 5% on manufacturing woes

Indian drugmaker Biocon closed more than 5% down at 628.65 rupees after trading on Mumbai on Thursday.

Mylan, Biocon Receive MAA

Mylan and Biocon announced that their co-developed biosimilar insulin glargine Semglee has received marketing authorization approval from the European Commission following the positive recommendation ...

Mylan, Biocon's Neulasta biosimilar OK'd by FDA

Fulphila, or pegfilgrastim-jmdb, from Mylan and Biocon was approved by the FDA to treat patients with non-myeloid cancer unde -More- 

Mylan and Biocon’s biosimilar to neulasta gains FDA approval

Mylan and Biocon have secured the US Food and Drug Administration’s (FDA) approval for their fulphila, which is a biosimilar...Read More... The post Mylan and Biocon’s biosimilar to neulasta g...

Biocon consolidated net up by 3% in Q4 to Rs.153 Cr, dividend of 20%

Biocon, a Rs.4,100 crore leading innovation─led bio─pharmaceutical company from Bengaluru, has posted small growth of 3 per cent in consolidated net profit during the fourth quarter ended March 20...

Biocon and Mylan win EU and Australian approval for biosimilar insulin glargine

Netherlands-incorporated Mylan and Indian development partner Biocon have been granted European approval…

U.S. FDA Approves Fulphila (pegfilgrastim-jmdb), the First Biosimilar to Neulasta

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, June 4, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and...

Drugs and Medications [0 Results]

None

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Biocon's target factory.

Promising effect of rapamycin on multiple sclerosis.

The routine therapies for relapsing-remitting multiple sclerosis (RRMS) are common disease-modifying medications, yet are not effective in all patients. The aim of the present clinical trial was to ev...

Clinical Trials [0 Results]

None

Companies [6 Associated Companies listed on BioPortfolio]

Biocon Limited

Established in 1978, Biocon Limited is India's largest biotechnology Company by revenue. The Group, promoted by Ms. Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven h...

BioCon Valley® GmbH

Born out of Germany´s "BioRegio" competition in 1996 BioCon Valley represents an interdisciplinary network in the field of modern life sciences and health care.Universities, research and health care ...

Biocon

Biocon is India's leading biotechnology enterprise. Over the past 25 years, we have evolved from an enzyme manufacturing company to a fully integrated biopharmaceutical enterprise, focused on healthca...

BIOCON, INC.

Since 1978 BIOCON has provided highly reliable, custom small animal research services to the region’s leading biomedical scientists. Whether your study involves small animal housing, breeding and co...

Biocon Ltd

More Information about "Biocon Ltd" on BioPortfolio

We have published hundreds of Biocon Ltd news stories on BioPortfolio along with dozens of Biocon Ltd Clinical Trials and PubMed Articles about Biocon Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biocon Ltd Companies in our database. You can also find out about relevant Biocon Ltd Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record